DURVALUMAB

BRAND NAME	IMFINZI
DRUG CLASS	Antineoplastic, monoclonal antibody (human)
AVAILABILITY	Vial contains 120 mg/2.4 mL or 500 mg/10 mL of durvalumab. Also contains histidine, histidine hydrochloride monohydrate, trehalose dihydrate and polysorbate-80.[1] The solution is clear to opalescent and colourless to slightly yellow.[1]
WARNINGS	The occupational hazard of intermittent low dose exposure to durvalumab is not known. Wear a mask and gloves when preparing the infusion solution to minimise exposure. Durvalumab is not a cytotoxic.
pH	No information
PREPARATION	Dilute the dose in 50–500 mL of a compatible fluid. Gently invert the bag to mix. **Do not shake**. The concentration should be 1–15 mg/mL.[1]
STABILITY	Vial: store at 2 to 8 °C. Do not freeze. Protect from light.[1] Infusion solution: stable for 12 hours at 25 °C or 24 hours at 2 to 8 °C.[1] **When prepared by pharmacy under aseptic conditions**: Infusion solution: stable for up to 24 hours at 25 °C and for 30 days at 2 to 8 °C.[2]
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Not recommended
IV injection	Not recommended
IV infusion	Infuse over 1 hour using a low protein-binding 0.2 or 0.22 micrometre inline filter.[1]
COMPATIBILITY	Glucose 5%[1], sodium chloride 0.9%[1]
INCOMPATIBILITY	No information
SPECIAL NOTES	Monitor the patient for infusion reactions and slow or stop the infusion if required.[1]

REFERENCES
1. Product information. Available from www.tga.gov.au. Accessed 30/03/2022.
2. Imfinzi 50 mg/mL concentrate for solution for infusion. Summary of product characteristics. Luton, UK: AstraZeneca UK. Approved 21/09/2018. Updated 30/11/2021. Available from www.medicines.org.uk. Accessed 30/03/2022.